Compare Ha Tay Pharmaceutical JSC with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
VND 6,403,584 Million (Small Cap)
90.00
NA
0.00%
0.18
6.43%
5.95
Revenue and Profits:
Net Sales:
692,880 Million
(Quarterly Results - Dec 2025)
Net Profit:
10,196 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-10.07%
0%
-10.07%
6 Months
-20.0%
0%
-20.0%
1 Year
-20.28%
0%
-20.28%
2 Years
159.62%
0%
159.62%
3 Years
67.8%
0%
67.8%
4 Years
62.26%
0%
62.26%
5 Years
28.6%
0%
28.6%
Ha Tay Pharmaceutical JSC for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
3.06%
EBIT Growth (5y)
-11.07%
EBIT to Interest (avg)
5.19
Debt to EBITDA (avg)
1.37
Net Debt to Equity (avg)
0.22
Sales to Capital Employed (avg)
1.44
Tax Ratio
20.78%
Dividend Payout Ratio
57.36%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
11.86%
ROE (avg)
13.65%
Valuation key factors
Factor
Value
P/E Ratio
90
Industry P/E
Price to Book Value
6.57
EV to EBIT
100.54
EV to EBITDA
77.20
EV to Capital Employed
5.71
EV to Sales
3.33
PEG Ratio
8.06
Dividend Yield
0.53%
ROCE (Latest)
5.68%
ROE (Latest)
7.33%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
692,879.70
638,800.80
8.47%
Operating Profit (PBDIT) excl Other Income
3,512.20
12,638.40
-72.21%
Interest
2,758.10
3,171.00
-13.02%
Exceptional Items
0.00
0.00
Consolidate Net Profit
10,196.30
11,524.20
-11.52%
Operating Profit Margin (Excl OI)
5.10%
10.00%
-0.49%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 8.47% vs 11.22% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is -11.52% vs -14.05% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
2,402,040.20
2,086,352.80
15.13%
Operating Profit (PBDIT) excl Other Income
64,854.40
96,993.30
-33.14%
Interest
13,056.30
14,307.40
-8.74%
Exceptional Items
0.00
0.00
Consolidate Net Profit
59,040.50
75,194.10
-21.48%
Operating Profit Margin (Excl OI)
16.90%
36.70%
-1.98%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 15.13% vs 4.35% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -21.48% vs -15.48% in Dec 2024
About Ha Tay Pharmaceutical JSC 
Ha Tay Pharmaceutical JSC
Pharmaceuticals & Biotechnology
Hatay Pharmaceutical Joint Stock Company (Hataphar) is a Vietnam-based pharmaceutical company. It is engaged in the manufacturing, marketing, wholesale and retail trading, import and export of pharmaceutical products, preparations and materials, vaccines, along with medical equipment and supplies. The Company also manufactures and trades cosmetic products, supplemental food, general chemicals and specialized chemicals for laboratory tests. Other activities include supermarket operations, office and apartment leasing, real estate brokerage services, as well as the provision of vocational training services. The Company announced that it has completed the acquisition of 50.626% stake in Ha Tay Pharmaceutical and Medical Equipments Joint Stock Company by the end of the third quarter of 2013.
Company Coordinates 
Company Details
10A Quang Trung, Ha Dong , HANOI None : None
Registrar Details






